Resolution of Anterior Uveal Infiltration of Acute Lymphoblastic Leukemia After Chimeric Antigen Receptor T-Cell Therapy.

Autor:	Takhar JS; University Hospitals Eye Institute, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Mehra AA; University Hospitals Eye Institute, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Kurup SK; University Hospitals Eye Institute, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Sobol WM; University Hospitals Eye Institute, Case Western Reserve University School of Medicine, Cleveland, OH, USA., Aslam R; Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA., Oduro KA; Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA., Echegaray JJ; University Hospitals Eye Institute, Case Western Reserve University School of Medicine, Cleveland, OH, USA.; Retina Consultants of Orlando, Altamonte Springs, FL, USA.
Jazyk:	angličtina
Zdroj:	Journal of vitreoretinal diseases [J Vitreoretin Dis] 2024 Aug 31, pp. 24741264241275247. Date of Electronic Publication: 2024 Aug 31.
DOI:	10.1177/24741264241275247
Abstrakt:	Purpose: To present a case of acute B-cell lymphoblastic leukemia (B-ALL) ocular relapse treated with chimeric antigen receptor T-cell (CAR T) therapy. Methods: A retrospective case review was evaluated. Results: A 69-year-old woman with a history of B - ALL presented with bilateral hypopyons and 3+ anterior chamber cells that responded to topical prednisolone. Six months later, she developed recurrent hypopyons, iris neovascularization, and iris nodularity in both eyes. A fine-needle aspiration biopsy confirmed ocular infiltration of B-ALL. A single infusion of CAR T therapy resulted in remission of the systemic and ocular findings. The clinical course was complicated by cytokine release syndrome and neurotoxicity, which improved with medical management. The patient remained in remission for 7 months after a single CAR T infusion. Conclusions: CAR T therapy may be effective in treating systemic leukemia and uveal infiltration, with an ocular side-effect profile and visual outcomes. The systemic side effects of CAR T therapy may be managed medically. Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of the article. (© The Author(s) 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu